45 results
424B3
VCNX
Vaccinex Inc
16 Apr 24
Prospectus supplement
4:55pm
Studies. We and others have shown that SEMA4D, the target of pepinemab, is highly expressed in head and neck cancer where it impedes recruitment
424B5
VCNX
Vaccinex Inc
28 Mar 24
Prospectus supplement for primary offering
1:27pm
, is highly expressed in head and neck cancer where it impedes recruitment and activation of cytotoxic T cells that
S-2
can attack the tumor while … and others have shown that SEMA4D, the target of pepinemab, is highly expressed in HNSCC where it impedes recruitment and activation of cytotoxic T
424B3
xvu8yk14vlscf
19 Jan 24
Prospectus supplement
4:40pm
424B4
dsne1yf t7fq
2 Oct 23
Prospectus supplement with pricing info
9:16am
424B3
8qx9ji dfgwx
11 Jul 23
Prospectus supplement
6:04am
424B5
nd2e9
19 May 23
Prospectus supplement for primary offering
5:13pm
8-K
EX-99.1
085elz9wt
10 Nov 22
Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab
9:05am